Mercury Clinical Research

What Mercury Clinical Research does

Mercury Clinical Research, Inc. is a privately held Site Management Organization (SMO) headquartered in Houston, Texas, that conducts and coordinates clinical trials on behalf of pharmaceutical companies and Contract Research Organizations (CROs). Founded approximately 2000, the company has operated for over 20 years in the greater Houston metropolitan area, partnering with a network of at least 7 board-certified Principal Investigators and 1 Sub-Investigator across six affiliated physician practices spanning pediatrics, neurology, internal medicine, family medicine, and neonatology in Houston, Sugar Land, Katy, and Tomball.

The company's core service offering is full-service clinical trial site management, including patient recruitment, study coordination, budget and contract negotiations, physician collaboration, and regulatory compliance support. It runs active enrolling trials across infectious disease, vaccines, cardiovascular, and neurology indications — notably Pfizer's BEETHOVEN C. difficile vaccine (NCT07282665), GSK's Twinkle-006 MMRV pediatric vaccine, AstraZeneca's AZD0780 PCSK9 inhibitor, and a Phase 3 CIDP monoclonal antibody trial. MCR was acquired by Neutra Corporation in 2024-2025 and currently markets itself to sponsors via direct enterprise sales, to physicians via partnership outreach, and to patient participants via a website (mercurycr.us.com) and organic social channels.

Revenue is generated on a professional-services basis: pharmaceutical sponsors fund each study and pay MCR per enrolled patient, per study visit, and per milestone completion. The company does not charge trial participants and offers no publicly disclosed pricing. Customer segments are three: (1) pharmaceutical companies and CROs as primary enterprise buyers, (2) affiliated physician practices as mid-market operational partners, and (3) patients as the participant pool. Distribution is direct and domestic (Texas only) through sponsor relationships and physician network partnerships.

Name

Mercury Clinical Research

Legal name

Mercury Clinical Research, Inc.

Website

https://mercurycr.us.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

Mercury Clinical Research is a Houston-based Site Management Organization that conducts and coordinates clinical trials for pharmaceutical sponsors and CROs across vaccines, infectious disease, cardiovascular, and neurology indications through a network of affiliated physician practices in the greater Houston area.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Site Network Operators & SMOs (HLAGACAA)

akta.pro secondary industries

Clinical Trial Site Operations & Study Coordination (HLAGACAE), Site Identification & Feasibility (HLAGACAB)

Keywords

• Clinical trial management
• Site management organization
• Clinical research services
• Patient recruitment
• Clinical trial coordination

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Trial Services: Revenue is generated through conducting clinical trials for pharmaceutical companies and CROs. The company provides full-service clinical trial management including study coordination, patient recruitment, data management, and regulatory compliance support. Sponsors fund the research studies, with payments structured around patient enrollment, study visits, and milestone completion.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Mercury Clinical Research operates as a Site Management Organization (SMO) providing full-service clinical trial management for pharmaceutical companies and CROs. Services span patient recruitment, study coordination, budget and contract negotiations, regulatory compliance support, and physician collaboration across multiple therapeutic areas including infectious disease, vaccines, cardiovascular, neurology, and pediatrics.

Product overview

Mercury Clinical Research is a Site Management Organization (SMO) that operates as a single, unified service offering rather than a platform-plus-modules architecture. Their core offering is full-service clinical trial management and coordination, which encompasses patient recruitment, budget and contract negotiations, physician collaboration, and regulatory support. The company works with leading pharmaceutical companies and CROs to conduct clinical trials across multiple therapeutic areas: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Influenza, COVID-19, Migraine, and Pediatric Vaccination. Their active clinical trials include the BEETHOVEN C. diff Vaccine Study, Twinkle-006 MMRV Vaccine Trial, Lullaby Chickenpox Prevention Program, AZD0780 Cardiovascular Trial, CAPTIVE CIDP Phase 3 Trial, and COVID-19 Antiviral Treatment Trial. The company has collaborated with physicians in the greater Houston area for over 20 years and provides services including access to groundbreaking studies, practice revenue growth opportunities, budget management, and training.

Differentiator

Problem solved

Functional benefit

Products and services

• Site Management Organization (SMO) Services Full-service clinical trial management and coordination for pharmaceutical companies and CROs, connecting sponsors with physician practices and patient populations for the conduct of clinical studies. Includes patient recruitment, study coordination, budget/contract negotiations, and regulatory compliance support.
• COVID-19 Antiviral Treatment Clinical Trial Pfizer-sponsored clinical trial evaluating a potential antiviral treatment for high-risk adults and adolescents with COVID-19 who have limited treatment options or are unable to take current treatments.
• BEETHOVEN Study - C. difficile Vaccine Clinical Trial (NCT07282665) Pfizer-sponsored vaccine clinical trial (NCT07282665) evaluating an investigational vaccine for the prevention of C. difficile infection in adults 65 years of age or older.
• Twinkle-006 MMRV Vaccine Clinical Trial Pediatric clinical trial investigating an investigational vaccine for the prevention of measles, mumps, rubella, and chickenpox diseases in children 4-6 years of age.
• Lullaby Program - Chickenpox Prevention Clinical Trial Pediatric vaccine clinical trial for chickenpox prevention enrolling children 12-15 months of age.
• AZD0780 Cardiovascular Clinical Trial Phase 2 clinical trial evaluating AZD0780, an experimental oral PCSK9 inhibitor, for reduction of LDL cholesterol levels and cardiovascular risk in adults.
• CAPTIVE Study - CIDP Phase 3 Clinical Trial Phase 3 randomized, double-blind, placebo-controlled trial evaluating DNTH103, a monoclonal antibody targeting the classical complement pathway, for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in adults.
• Future Studies Registry Registry for individuals interested in contributing to future clinical studies, including early-stage and non-interventional research, supporting pipeline enrollment for upcoming trials.

Quantifiable outcome

• 39 potential lives saved through blood drive partnership
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered minor and flagship.

• Gulf Coast Blood CenterminorStrategic or Co-development Partner · 18 July 2025Annual blood drive partnership. MCR team and supporters participate in community blood donation events. The partnership potentially saved 39 lives through the July 2025 blood drive, continuing a multi-year tradition of community service.
• PfizerflagshipStrategic or Co-development Partner · 1 January 2025Pfizer hand-selected Dr. Yudovich and Dr. Garcia from MCR to represent the organization in consulting on the design of new pneumococcal vaccines. This prestigious opportunity places MCR at the forefront of pediatric vaccine innovation and demonstrates Pfizer's recognition of MCR's expertise.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medpace Holdings: Medpace is a mid-to-large full-service CRO that runs its own dedicated clinical site infrastructure as part of its integrated delivery model. It overlaps with Mercury's offering through site operations and Phase 2-3 trial management, though at significantly greater scale.
• IQVIA: IQVIA is the largest global CRO with a substantial site-management and site-network arm (IQVIA Site Solutions) that competes for sponsor site placements across all major therapeutic areas Mercury serves.

Regional players

• Panthera Clinical Research: Panthera operates a multi-site SMO network primarily in the UK with a similar PI-driven, multi-therapeutic model. It is comparable to Mercury as a private site-network operator competing for global sponsor allocations.

Direct peers

• Velocity Clinical Research: Velocity is a US-focused, multi-therapeutic SMO/site network that runs Phase 2-4 trials through affiliated principal investigators across many metros. It is the closest direct comparable to Mercury in business model (PI-driven multi-site SMO) and target customer base (large pharma/CRO sponsors).
• Flourish Research: Flourish Research is an integrated research site network operating multiple locations and therapeutic areas with embedded PIs. It directly competes with Mercury for sponsor trial placement and physician-practice partnership models.
• Javara Inc. Javara is an integrated research organization that embeds clinical trials into physician practices, very similar to Mercury's model of partnering with independent Houston practices. It is a direct competitor for sponsor site-selection decisions.

Peers

• ICON plc:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/mercurycr
• LinkedInlinkedin.com/company/mercuryclinicalresearch
• Instagraminstagram.com/mcr_htx
• Xx.com/mercury_cr

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mercury Clinical Research